Vivos Therapeutics, Inc. (VVOS)

NCM – Цена в реальном времени. Валюта: USD

0.45

+0.01 (3.13%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

0.45

-0.00 (-0.13%)

После закрытия: Jun 26, 2026, 6:39 PM EDT

Vivos Therapeutics, Inc. (VVOS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Видео

No Data

Пресс-релизы

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Видео

No Data

Пресс-релизы

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Search stocks

Vivos Therapeutics, Inc. (VVOS)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Видео

No Data

Пресс-релизы

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing

Vivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call Transcript

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update

Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

Видео

No Data

Пресс-релизы

Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering

Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients

Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026

Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing